Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Role of kinesins in directed adenovirus transport and cytoplasmic exploration.

Zhou J, Scherer J, Yi J, Vallee RB.

PLoS Pathog. 2018 May 21;14(5):e1007055. doi: 10.1371/journal.ppat.1007055. eCollection 2018 May.

2.

Ten Tips Nephrologists Wish the Palliative Care Team Knew About Caring for Patients with Kidney Disease.

Bansal AD, Leonberg-Yoo A, Schell JO, Scherer JS, Jones CA.

J Palliat Med. 2018 Apr;21(4):546-551. doi: 10.1089/jpm.2018.0087.

PMID:
29596042
3.

Active Brazilian crack cocaine users: nutritional, anthropometric, and drug use profiles.

Escobar M, Scherer JN, Soares CM, Guimarães LSP, Hagen ME, von Diemen L, Pechansky F.

Rev Bras Psiquiatr. 2018 Feb 15:0. doi: 10.1590/1516-4446-2017-2409. [Epub ahead of print]

4.

Leptin levels and its correlation with crack-cocaine use severity: A preliminary study.

Escobar M, Scherer JN, Ornell F, Bristot G, Soares CM, Guimarães LSP, Von Diemen L, Pechansky F.

Neurosci Lett. 2018 Apr 3;671:56-59. doi: 10.1016/j.neulet.2018.02.009. Epub 2018 Feb 5.

PMID:
29421542
5.

Metal selectivity determinants in a family of transition metal transporters.

Podar D, Scherer J, Noordally Z, Herzyk P, Nies D, Sanders D.

J Biol Chem. 2018 Jan 5;293(1):402. doi: 10.1074/jbc.AAC117.001146. No abstract available.

6.

Hepatitis C: clinical and biological features related to different forms of cocaine use.

Schuch-Goi SB, Scherer JN, Kessler FHP, Sordi AO, Pechansky F, von Diemen L.

Trends Psychiatry Psychother. 2017 Oct-Dec;39(4):285-292. doi: 10.1590/2237-6089-2016-0076.

7.

Anxiety and depression symptoms in Brazilian sexual minority ecstasy and LSD users.

Remy LS, Scherer J, Guimarães L, Surratt HL, Kurtz SP, Pechansky F, Kessler F.

Trends Psychiatry Psychother. 2017 Oct-Dec;39(4):239-246. doi: 10.1590/2237-6089-2016-0081. Epub 2017 Nov 13.

8.

Comparison of Cocaine/Crack Biomarkers Concentrations in Oral Fluid, Urine and Plasma Simultaneously Collected From Drug Users.

Fiorentin TR, Scherer JN, Marcelo MCA, Sousa TRV, Pechansky F, Ferrão MF, Limberger RP.

J Anal Toxicol. 2018 Mar 1;42(2):69-76. doi: 10.1093/jat/bkx085.

PMID:
29140478
9.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.

Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC, Grayzel D, Schuetz TJ, de Hoon J.

Front Pharmacol. 2017 Oct 17;8:740. doi: 10.3389/fphar.2017.00740. eCollection 2017.

10.

Functional Carboxy-Terminal Fluorescent Protein Fusion to Pseudorabies Virus Small Capsid Protein VP26.

Hogue IB, Jean J, Esteves AD, Tanneti NS, Scherer J, Enquist LW.

J Virol. 2017 Dec 14;92(1). pii: e01193-17. doi: 10.1128/JVI.01193-17. Print 2018 Jan 1.

11.

Crack-cocaine users have less family cohesion than alcohol users.

Marchi NC, Scherer JN, Pachado MP, Guimarães LS, Siegmund G, de Castro MN, Halpern S, Benzano D, Formigoni ML, Cruz M, Pechansky F, Kessler FH.

Rev Bras Psiquiatr. 2017 Oct-Dec;39(4):346-351. doi: 10.1590/1516-4446-2016-2091. Epub 2017 Aug 30.

12.

Guide wire insertion for percutaneous LC2 screws in acetabular and pelvic ring fixation using a transpedicular working cannula.

Scherer J, Guy P, Lefaivre KA, Pape HC, Werner CML, Osterhoff G.

Injury. 2017 Oct;48(10):2360-2364. doi: 10.1016/j.injury.2017.08.049. Epub 2017 Aug 25.

PMID:
28859845
13.

Anterior subcutaneous internal fixation of the pelvis - what rod-to-bone distance is anatomically optimal?

Osterhoff G, Aichner EV, Scherer J, Simmen HP, Werner CML, Feigl GC.

Injury. 2017 Oct;48(10):2162-2168. doi: 10.1016/j.injury.2017.08.047. Epub 2017 Aug 25.

PMID:
28859843
14.

Building an Outpatient Kidney Palliative Care Clinical Program.

Scherer JS, Wright R, Blaum CS, Wall SP.

J Pain Symptom Manage. 2018 Jan;55(1):108-116.e2. doi: 10.1016/j.jpainsymman.2017.08.005. Epub 2017 Aug 10. Erratum in: J Pain Symptom Manage. 2018 Mar;55(3):e12.

PMID:
28803081
15.

Terahertz-Driven Luminescence and Colossal Stark Effect in CdSe-CdS Colloidal Quantum Dots.

Pein BC, Chang W, Hwang HY, Scherer J, Coropceanu I, Zhao X, Zhang X, Bulović V, Bawendi M, Nelson KA.

Nano Lett. 2017 Sep 13;17(9):5375-5380. doi: 10.1021/acs.nanolett.7b01837. Epub 2017 Aug 23.

PMID:
28786683
16.

[Clinical and social vulnerabilities in crack users according to housing status: a multicenter study in six Brazilian state capitals].

Halpern SC, Scherer JN, Roglio V, Faller S, Sordi A, Ornell F, Dalbosco C, Pechansky F, Kessler F, Diemen LV.

Cad Saude Publica. 2017 Jul 3;33(6):e00037517. doi: 10.1590/0102-311X00037517. Portuguese.

17.

Treatment decisions for older adults with advanced chronic kidney disease.

Rosansky SJ, Schell J, Shega J, Scherer J, Jacobs L, Couchoud C, Crews D, McNabney M.

BMC Nephrol. 2017 Jun 19;18(1):200. doi: 10.1186/s12882-017-0617-3. Review.

18.

Reliability of point-of-collection testing devices for drugs of abuse in oral fluid: A systematic review and meta-analysis.

Scherer JN, Fiorentin TR, Borille BT, Pasa G, Sousa TRV, von Diemen L, Limberger RP, Pechansky F.

J Pharm Biomed Anal. 2017 Sep 5;143:77-85. doi: 10.1016/j.jpba.2017.05.021. Epub 2017 May 13. Review.

PMID:
28577420
19.

Simultaneous determination of cocaine/crack and its metabolites in oral fluid, urine and plasma by liquid chromatography-mass spectrometry and its application in drug users.

Fiorentin TR, D'Avila FB, Comiran E, Zamboni A, Scherer JN, Pechansky F, Borges PEM, Fröehlich PE, Limberger RP.

J Pharmacol Toxicol Methods. 2017 Jul;86:60-66. doi: 10.1016/j.vascn.2017.04.003. Epub 2017 Apr 7.

PMID:
28395991
20.

Oral Fluid Testing for Cocaine: Analytical Evaluation of Two Point-of-Collection Drug Screening Devices.

Scherer JN, Fiorentin TR, Sousa TRV, Limberger RP, Pechansky F.

J Anal Toxicol. 2017 Jun 1;41(5):392-398. doi: 10.1093/jat/bkx018.

PMID:
28334841
21.

Factors Affecting Functional Impairment among Elderly Germans - Results of a Longitudinal Study.

Hajek A, Luck T, Brettschneider C, Posselt T, Lange C, Wiese B, Steinmann S, Weyerer S, Werle J, Pentzek M, Fuchs A, Stein J, Bickel H, Mösch E, Wagner M, Heser K, Maier W, Scherer JM, Riedel-Heller SG, König HH.

J Nutr Health Aging. 2017;21(3):299-306. doi: 10.1007/s12603-016-0771-5.

PMID:
28244570
22.

Illness Trajectories: Description and Clinical Use #326.

Comstock Barker P, Scherer JS.

J Palliat Med. 2017 Apr;20(4):426-427. doi: 10.1089/jpm.2016.0554. Epub 2017 Feb 2. No abstract available.

PMID:
28151051
23.

Neuromuscular responses of the plantar flexors to whole-body vibration.

Harwood B, Scherer J, Brown RE, Cornett KMD, Kenno KA, Jakobi JM.

Scand J Med Sci Sports. 2017 Dec;27(12):1569-1575. doi: 10.1111/sms.12803. Epub 2016 Dec 29.

PMID:
28033657
24.

Erratum to "Prevalence of driving under the influence of psychoactive substances and road traffic crashes among Brazilian crack-using drivers" [Drug Alcohol Depend. 168 (2016) 255-262].

Scherer JN, Silvestrin R, Ornell F, Roglio V, Sousa TR; Brazilian Crack Group, Von Diemen L, Kessler FH, Pechansky F.

Drug Alcohol Depend. 2017 Feb 1;171:e227. doi: 10.1016/j.drugalcdep.2016.11.004. Epub 2016 Dec 21. No abstract available.

PMID:
28012714
25.

Prevalence of driving under the influence of psychoactive substances and road traffic crashes among Brazilian crack-using drivers.

Scherer JN, Silvestrin R, Ornell F, Roglio V, Sousa TRV; Brazilian Crack Group, Von Diemen L, Kessler FHP, Pechansky F.

Drug Alcohol Depend. 2016 Nov 1;168:255-262. doi: 10.1016/j.drugalcdep.2016.09.017. Epub 2016 Oct 1. Erratum in: Drug Alcohol Depend. 2017 Feb 1;171:e227.

PMID:
27736679
26.

Sleep Disorders, Restless Legs Syndrome, and Uremic Pruritus: Diagnosis and Treatment of Common Symptoms in Dialysis Patients.

Scherer JS, Combs SA, Brennan F.

Am J Kidney Dis. 2017 Jan;69(1):117-128. doi: 10.1053/j.ajkd.2016.07.031. Epub 2016 Sep 29. Review.

27.

Practice Change Is Needed for Dialysis Decision Making with Older Adults with Advanced Kidney Disease.

Scherer JS, Moss AH.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1732-1734. doi: 10.2215/CJN.08770816. Epub 2016 Sep 22. No abstract available.

28.

Dual-color Herpesvirus Capsids Discriminate Inoculum from Progeny and Reveal Axonal Transport Dynamics.

Scherer J, Yaffe ZA, Vershinin M, Enquist LW.

J Virol. 2016 Aug 31. pii: JVI.01122-16. [Epub ahead of print]

29.

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.

Berger KL, Sarrazin C, Nelson DR, Scherer J, Sha N, Marquis M, Côté-Martin A, Vinisko R, Stern JO, Mensa FJ, Kukolj G.

PLoS One. 2016 Aug 5;11(8):e0160668. doi: 10.1371/journal.pone.0160668. eCollection 2016.

30.

High levels of brain-derived neurotrophic factor are associated with treatment adherence among crack-cocaine users.

Scherer JN, Schuch S, Ornell F, Sordi AO, Bristot G, Pfaffenseller B, Kapczinski F, Kessler FHP, Fumagalli F, Pechansky F, von Diemen L.

Neurosci Lett. 2016 Sep 6;630:169-175. doi: 10.1016/j.neulet.2016.07.050. Epub 2016 Jul 26.

PMID:
27473943
31.

Exocytosis of Alphaherpesvirus Virions, Light Particles, and Glycoproteins Uses Constitutive Secretory Mechanisms.

Hogue IB, Scherer J, Enquist LW.

MBio. 2016 Jun 7;7(3). pii: e00820-16. doi: 10.1128/mBio.00820-16.

32.

Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.

Nishiguchi S, Urano Y, Suzaki K, Taniguchi A, Scherer J, Berger KL, Quinson AM, Stern JO, Omata M.

Hepatol Res. 2017 Mar;47(3):E142-E151. doi: 10.1111/hepr.12741. Epub 2016 Aug 10.

PMID:
27153246
33.

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P.

Ann Hepatol. 2016 May-Jun;15(3):333-49. doi: 10.5604/16652681.1198803.

PMID:
27049487
34.

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team.

PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.

35.

NBOMe: a new dangerous drug similar to LSD.

Remy L, Marchi N, Scherer J, Fiorentin TR, Limberger R, Pechansky F, Kessler F.

Rev Bras Psiquiatr. 2015 Oct-Dec;37(4):351-2. doi: 10.1590/1516-4446-2015-1774. No abstract available. Erratum in: Rev Bras Psiquiatr. 2016 Mar;38(1):89.

36.

Trace elements concentrations in Buff-breasted Sandpiper sampled in Lagoa do Peixe National Park, Southern Brazil.

Scherer JF, Scherer AL, Barbieri E, Petry MV, Valiati VH.

Braz J Biol. 2015 Nov;75(4):932-5. doi: 10.1590/1519-6984.02914. Epub 2015 Nov 10.

37.

Fluorescent Protein Approaches in Alpha Herpesvirus Research.

Hogue IB, Bosse JB, Engel EA, Scherer J, Hu JR, Del Rio T, Enquist LW.

Viruses. 2015 Nov 19;7(11):5933-61. doi: 10.3390/v7112915. Review.

38.

Using Masculine Capital to Understand the Role of a Sport Program in the Lives of Men From a Western Canadian Inner City.

Holt NL, Scherer J, Koch J.

J Sport Exerc Psychol. 2015 Oct;37(5):523-33. doi: 10.1123/jsep.2015-0109.

PMID:
26524098
39.

Improving advance care planning and bereavement outcomes.

Scherer JS, Holley JL.

Am J Kidney Dis. 2015 Nov;66(5):735-7. doi: 10.1053/j.ajkd.2015.08.015. No abstract available.

PMID:
26498412
40.

The Role of Time-Limited Trials in Dialysis Decision Making in Critically Ill Patients.

Scherer JS, Holley JL.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):344-53. doi: 10.2215/CJN.03550315. Epub 2015 Oct 8. Review.

41.

A path to practical Solar Pumped Lasers via Radiative Energy Transfer.

Reusswig PD, Nechayev S, Scherer JM, Hwang GW, Bawendi MG, Baldo MA, Rotschild C.

Sci Rep. 2015 Oct 5;5:14758. doi: 10.1038/srep14758.

42.

[Safety cell therapeutics/cell based medicinal products (CBMP)].

Scherer J, Seitz R.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1199-200. doi: 10.1007/s00103-015-2254-y. German. No abstract available.

PMID:
26391096
43.

[Classification of cell-based medicinal products and legal implications: An overview and an update].

Scherer J, Flory E.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1201-6. doi: 10.1007/s00103-015-2235-1. Review. German.

PMID:
26369760
44.

An Untraveled Road: The Integration of Palliative Care with Nephrology.

Scherer JS.

J Palliat Med. 2015 Oct;18(10):895-6. doi: 10.1089/jpm.2015.0107. Epub 2015 Aug 25. No abstract available.

PMID:
26305183
45.

Factors associated with a more rapid recovery after anterior cruciate ligament reconstruction using multivariate analysis.

Scherer JE, Moen MH, Weir A, Schmikli SL, Tamminga R, van der Hoeven H.

Knee. 2016 Jan;23(1):121-6. doi: 10.1016/j.knee.2015.06.009. Epub 2015 Aug 8.

PMID:
26260243
46.

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.

Berger KL, Scherer J, Ranga M, Sha N, Stern JO, Quinson AM, Kukolj G.

Antimicrob Agents Chemother. 2015 Oct;59(10):6017-25. doi: 10.1128/AAC.00932-15. Epub 2015 Jul 20.

47.

Oxidized proportion of muscle coenzyme Q10 increases with age in healthy children.

Niklowitz P, Scherer J, Döring F, Paulussen M, Menke T.

Pediatr Res. 2015 Oct;78(4):365-70. doi: 10.1038/pr.2015.124. Epub 2015 Jun 24.

PMID:
26107394
48.

Detecting initiation or risk for initiation of substance use before high school during pediatric well-child check-ups.

Ridenour TA, Willis D, Bogen DL, Novak S, Scherer J, Reynolds MD, Zhai ZW, Tarter RE.

Drug Alcohol Depend. 2015 May 1;150:54-62. doi: 10.1016/j.drugalcdep.2015.02.013. Epub 2015 Mar 2.

49.

What's your plan? Why a well-thought-out career plan is essential in today's environment.

Broscio MA, Scherer JE.

Healthc Exec. 2014 Nov-Dec;29(6):60-2. No abstract available.

PMID:
25665302
50.

High-performance shortwave-infrared light-emitting devices using core-shell (PbS-CdS) colloidal quantum dots.

Supran GJ, Song KW, Hwang GW, Correa RE, Scherer J, Dauler EA, Shirasaki Y, Bawendi MG, Bulović V.

Adv Mater. 2015 Feb 25;27(8):1437-42. doi: 10.1002/adma.201404636. Epub 2015 Jan 8.

PMID:
25639896

Supplemental Content

Loading ...
Support Center